---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-037559"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T01:31:25.309093+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma prices $175.3M public offering of shares and pre-funded warrants

## Summary
- Priced 4,488,159 ordinary shares at $19.00/share and 4,736,841 pre-funded warrants at $18.9999 each.
- Gross proceeds of approximately $175.3 million before underwriting discounts and expenses.
- Underwriters granted 30-day option for up to 1,383,750 additional shares, exercised in full.
- Net proceeds expected to be approximately $188.8 million including option exercise.
- Offering closed on February 16, 2024; Jefferies, Leerink, Piper Sandler, RBC Capital Markets as joint book-runners.

## SEC filing metadata
- accession: 0001193125-24-037559
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312524037559/0001193125-24-037559-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312524037559/d790577d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-037559
- JSON: https://secwatch.observer/filing/0001193125-24-037559.json
- Plain text: https://secwatch.observer/filing/0001193125-24-037559.txt

## Key facts
- Material Agreements
  NewAmsterdam Pharma Co N.V. entered into Underwriting Agreement with Jefferies LLC, Leerink Partners LLC, Piper Sandler & Co. and RBC Capital Markets, LLC, as representatives of the several underwriters valued at $188.8 million (effective 2024-02-13).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Jefferies LLC, Leerink Partners LLC, Piper Sandler & Co. and RBC Capital Markets, LLC, as representatives of the several underwriters
  - Value: $188.8 million
  - Effective: 2024-02-13
  source text: On February 13, 2024, NewAmsterdam Pharma Company N.V. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Leerink Partners LLC, Piper Sandler & Co. and RBC Capital Markets, LLC, as representatives of the several underwriters listed on Schedule A thereto (the “Underwriters”), related to an underwritten public offering (the “Offering”) of 4,488,159 of the Company’s ordinary shares, nominal value €0.12 per share (the “Ordinary Shares”), at a public offering price of $19.00 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1936258/000119312524037559/0001193125-24-037559-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.